GlassScriptPhysician profile
Irfan Ansari
NPI 1497711162
$2,121.53
in general payments reported to CMS, 2019-2025
26 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $144 · 2021: $216 · 2022: $362 · 2023: $381 · 2024: $123 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.53 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Astrazeneca Pharmaceuticals LP | $249.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.77 | 2019 | |
| Zimvie INC. | $148.38 | 2023 | |
| Pfizer INC. | $148.03 | 2019-2024 | |
| Medtronic, INC. | $123.07 | 2022 | |
| Allergan, INC. | $97.96 | 2019-2022 | |
| Amarin Pharma, INC. | $74.99 | 2019 | |
| Merz Pharmaceuticals, LLC | $72.79 | 2022-2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $60.74 | 2022 | |
| Orexo US, INC. | $49.53 | 2021 | |
| Pacira Therapeutics, INC. | $44.72 | 2019 | |
| Novo Nordisk INC | $42.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.28 | 2021 | |
| Amgen INC. | $39.72 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $37.88 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $37.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $36.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.47 | 2021 | |
| Fidia Pharma USA INC. | $29.76 | 2025 | Triluron, Hymovis |
| Catalyst Pharmaceuticals, INC. | $29.72 | 2020 | |
| Averitas Pharma INC. | $28.31 | 2023 | Qutenza |
| Lilly USA, LLC | $22.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.59 | 2022 | |
| Boston Scientific Corporation | $15.28 | 2020 | |
| Stratus Medical, LLC | $10.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.